Retinoid receptors in the human endometrium and its disorders: a possible modulator of 17 beta-hydroxysteroid dehydrogenase
- PMID:11397877
- DOI: 10.1210/jcem.86.6.7546
Retinoid receptors in the human endometrium and its disorders: a possible modulator of 17 beta-hydroxysteroid dehydrogenase
Abstract
Retinoids have recently been proposed to modulate estrogenic actions in various sex steroid-dependent neoplasms, but little has been studied in human endometrial disorders. Therefore, in this study, we first examined the immunolocalization of retinoic acid receptor alpha, beta, and gamma, and retinoid X receptor (RXR) alpha, beta, and gamma in 20 normal cycling human endometria, 34 endometrial hyperplasia, and 46 endometrioid endometrial adenocarcinomas. We then correlated these findings with other clinicopathological parameters, especially in the correlation between retinoid receptor subtypes and the status of steroid hormone receptors, 17 beta-hydroxysteroid dehydrogenase (17 beta-HSD) and aromatase. We also then examined the effects of retinoic acid on the expression of 17 beta-HSD type 2 in cell lines derived from endometrial carcinoma using Northern blotting analysis to examine the possible roles of retinoids in in situ endometrial estrogen metabolism. Among these six retinoid receptors examined, RXR gamma immunoreactivity was exclusively detected in the epithelial cells of the secretory phase endometrium but not of the proliferative phase, which was well correlated with 17 beta-HSD type 2 immunolocalization. However, in endometrial hyperplasia, RXR gamma was not correlated with 17 beta-HSD type 2. In endometrioid endometrial adenocarcinoma, there was a statistically significant correlation between 17 beta-HSD type 2 immunoreactivity and RXR gamma labeling index (LI) (P < 0.001) and between RXR gamma LI and progesterone receptor LI (r = 0.501, P = 0.003). A significant inverse correlation was also detected between RXR gamma LI and patient age (r = 0.449, P = 0.015). No statistically significant correlation was obtained between LIs of receptors and other clinicopathological parameters including the status of intratumoral aromatase examined by immunohistochemistry. In the endometrial carcinoma cell line, RL95-2, retinoic acid markedly increased the level of 17 beta-HSD type 2 messenger RNA in a time- and dose-dependent manner. These results all suggest that retinoic acids may be involved in modulation of in situ estrogen metabolism in both normal and neoplastic human endometrium possibly through RXR gamma by stimulating the expression of 17 beta-HSD type 2.
Similar articles
- The analyses of 17beta-hydroxysteroid dehydrogenase isozymes in human endometrial hyperplasia and carcinoma.Utsunomiya H, Suzuki T, Kaneko C, Takeyama J, Nakamura J, Kimura K, Yoshihama M, Harada N, Ito K, Konno R, Sato S, Okamura K, Sasano H.Utsunomiya H, et al.J Clin Endocrinol Metab. 2001 Jul;86(7):3436-43. doi: 10.1210/jcem.86.7.7661.J Clin Endocrinol Metab. 2001.PMID:11443221
- Expression of androgen receptor and 5alpha-reductases in the human normal endometrium and its disorders.Ito K, Suzuki T, Akahira J, Moriya T, Kaneko C, Utsunomiya H, Yaegashi N, Okamura K, Sasano H.Ito K, et al.Int J Cancer. 2002 Jun 10;99(5):652-7. doi: 10.1002/ijc.10394.Int J Cancer. 2002.PMID:12115497
- 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.Ariga N, Moriya T, Suzuki T, Kimura M, Ohuchi N, Satomi S, Sasano H.Ariga N, et al.Anticancer Res. 2000 Mar-Apr;20(2B):1101-8.Anticancer Res. 2000.PMID:10810403
- 17-beta-hydroxysteroid dehydrogenase in human breast and endometrial carcinoma. A new development in intracrinology.Sasano H, Suzuki T, Takeyama J, Utsunomiya H, Ito K, Ariga N, Moriya T.Sasano H, et al.Oncology. 2000;59 Suppl 1:5-12. doi: 10.1159/000055281.Oncology. 2000.PMID:11096350Review.
- 17Beta-hydroxysteroid dehydrogenases in human endometrium and its disorders.Ito K, Utsunomiya H, Suzuki T, Saitou S, Akahira J, Okamura K, Yaegashi N, Sasano H.Ito K, et al.Mol Cell Endocrinol. 2006 Mar 27;248(1-2):136-40. doi: 10.1016/j.mce.2005.11.038. Epub 2006 Jan 6.Mol Cell Endocrinol. 2006.PMID:16406263Review.
Cited by
- The role of lipoxin A4 in endometrial biology and endometriosis.Canny GO, Lessey BA.Canny GO, et al.Mucosal Immunol. 2013 May;6(3):439-50. doi: 10.1038/mi.2013.9. Epub 2013 Mar 13.Mucosal Immunol. 2013.PMID:23485944Free PMC article.Review.
- Altered expression of 17‑β‑hydroxysteroid dehydrogenase type 2 and its prognostic significance in non‑small cell lung cancer.Drzewiecka H, Jarmołowska-Jurczyszyn D, Kluk A, Gałęcki B, Dyszkiewicz W, Jagodziński PP.Drzewiecka H, et al.Int J Oncol. 2020 Jun;56(6):1352-1372. doi: 10.3892/ijo.2020.5014. Epub 2020 Mar 19.Int J Oncol. 2020.PMID:32236582Free PMC article.
- Expression of retinoic acid receptors in human endometrial carcinoma.Tanabe K, Utsunomiya H, Tamura M, Niikura H, Takano T, Yoshinaga K, Nagase S, Suzuki T, Ito K, Matsumoto M, Hayashi S, Yaegashi N.Tanabe K, et al.Cancer Sci. 2008 Feb;99(2):267-71. doi: 10.1111/j.1349-7006.2007.00684.x.Cancer Sci. 2008.PMID:18271925Free PMC article.
- Vitamins in Gynecologic Malignancies.Wierzbowska N, Olszowski T, Chlubek D, Kozłowski M, Cymbaluk-Płoska A.Wierzbowska N, et al.Nutrients. 2024 May 5;16(9):1392. doi: 10.3390/nu16091392.Nutrients. 2024.PMID:38732639Free PMC article.Review.
- Placenta defects and embryonic lethality resulting from disruption of mouse hydroxysteroid (17-beta) dehydrogenase 2 gene.Rantakari P, Strauss L, Kiviranta R, Lagerbohm H, Paviala J, Holopainen I, Vainio S, Pakarinen P, Poutanen M.Rantakari P, et al.Mol Endocrinol. 2008 Mar;22(3):665-75. doi: 10.1210/me.2007-0257. Epub 2007 Nov 29.Mol Endocrinol. 2008.PMID:18048640Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Research Materials